You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 康希諾生物-B(6185.HK)高開逾3%再創新高 市值突破560億港元
格隆匯 05-21 09:29
格隆匯5月21日丨康希諾生物-B(6185.HK)高開3.82%,報255.4港元續創上市新高,今年迄今已累漲333.25%,暫成交738萬港元,最新總市值568億港元。康希諾近日發公告稱,公司於5月15日獲得加拿大衞生部關於重組新型冠狀病毒疫苗(腺病毒載體)(Ad5-nCoV)臨牀試驗申請批准。Ad5-nCoV採用基因工程方法構建,擬用於預防新型冠狀病毒感染引起的疾病。此外據悉,康希諾生物和加拿大的Precision NanoSystems(PNI)公司聯合宣佈,雙方達成協議,將利用PNI公司的獨有RNA疫苗技術平台,開發基於mRNA脂質納米顆粒(mRNA-LNP)技術的疫苗。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account